<DOC>
	<DOCNO>NCT00005793</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop cancer cell divide stop grow die . Combining one drug may kill cancer cell . PURPOSE : Phase I/II trial study effectiveness combination chemotherapy treat patient previously untreated acute myeloid leukemia .</brief_summary>
	<brief_title>A Phase I/II Study Induction Chemotherapy With Daunorubicin , Cytarabine , Topotecan Etoposide</brief_title>
	<detailed_description>OBJECTIVES : - Determine maximum tolerate dose ( MTD ) topotecan combine daunorubicin , cytarabine , etoposide patient de novo acute myeloid leukemia . - Determine efficacy regimen MTD topotecan measure complete response rate patient population . - Determine day hospitalization number infection associated regimen patient . - Correlate serum level topotecan etoposide expression topoisomerase I II tumor cell peripheral blood mononuclear cell ( PBMN ) , well toxicity response rate patient . - Correlate tumor cell PBMN expression activity topoisomerase I II hematological toxicity clinical response patient . - Correlate level activation STAT signal protein expression bcl-2 family proteins response chemotherapy patient . OUTLINE : This dose-escalation study topotecan ( phase I ) follow response rate-determination ( phase II ) study . Patients receive induction chemotherapy daunorubicin IV 10-15 minute day 1-3 , cytarabine IV continuously day 1-5 , topotecan IV continuously day 6-8 , etoposide IV 60 minute day 9 10 . Within 4 week hematologic recovery , patient achieve remission induction receive consolidation chemotherapy cytarabine IV 1 hour every 12 hour day 1 , 3 , 5 . Subsequent course consolidation chemotherapy begin within 2 week documentation hematologic recovery prior consolidation course . Consolidation chemotherapy continue 4 course absence unacceptable toxicity disease progression . Cohorts 3-6 patient receive escalate dos topotecan maximum tolerate dose ( MTD ) determine . The MTD define dose precede 2 3 2 6 patient experience dose-limiting toxicity . Once MTD determine , additional patient accrue receive induction chemotherapy recommend phase II dose . Patients follow 1 month , every 2 month 1 year , every 3 month 2 year , every 6 month 2 year , annually thereafter . PROJECTED ACCRUAL : A total 3-36 patient ( phase I ) additional 24-27 patient ( phase II ) accrue study within 4 year .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Daunorubicin</mesh_term>
	<mesh_term>Etoposide phosphate</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Topotecan</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm newly diagnose , previously untreated acute myeloid leukemia ( AML ) All FAB type , M0M7 , exclude M3 No AML myelodysplastic syndrome PATIENT CHARACTERISTICS : Age : 16 59 Performance status : Eastern Cooperative Oncology Group ( ECOG ) 02 Life expectancy : Not specify Hematopoietic : Not specify Hepatic : Bilirubin le 2 mg/dL SGOT/SGPT normal unless due leukemic disease Alkaline phosphatase normal unless due leukemic disease Renal : Creatinine great 2.0 mg/dL OR Creatinine clearance great 60 mL/min Cardiovascular : Ejection fraction least 50 % MUGA No myocardial infarction serious ventricular arrhythmia within past 6 month Other : Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception No prior malignancy within past 5 year except resected skin cancer HIV negative PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : No prior topotecan DNA topoisomerase I inhibitor ( e.g. , irinotecan , aminocamptothecin , nitrocamptothecin ) etoposide prior malignancy Endocrine therapy : Not specify Radiotherapy : Not specify Surgery : Not specify</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>59 Years</maximum_age>
	<verification_date>September 2012</verification_date>
	<keyword>untreated adult acute myeloid leukemia</keyword>
	<keyword>adult acute erythroid leukemia ( M6 )</keyword>
	<keyword>adult acute myeloblastic leukemia without maturation ( M1 )</keyword>
	<keyword>adult acute myeloblastic leukemia maturation ( M2 )</keyword>
	<keyword>adult acute myelomonocytic leukemia ( M4 )</keyword>
	<keyword>adult acute monoblastic leukemia ( M5a )</keyword>
	<keyword>adult acute megakaryoblastic leukemia ( M7 )</keyword>
	<keyword>adult acute monocytic leukemia ( M5b )</keyword>
	<keyword>adult acute minimally differentiate myeloid leukemia ( M0 )</keyword>
	<keyword>adult acute myeloid leukemia 11q23 ( MLL ) abnormality</keyword>
	<keyword>adult acute myeloid leukemia inv ( 16 ) ( p13 ; q22 )</keyword>
	<keyword>adult acute myeloid leukemia ( 16 ; 16 ) ( p13 ; q22 )</keyword>
	<keyword>adult acute myeloid leukemia ( 8 ; 21 ) ( q22 ; q22 )</keyword>
</DOC>